C Isles
University of Edinburgh
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by C Isles.
Circulation | 2001
Dilys J. Freeman; John Norrie; Naveed Sattar; R. Dermot G. Neely; Stuart M. Cobbe; Ian Ford; C Isles; A.Ross Lorimer; Peter W. Macfarlane; J. H. McKillop; Christopher J. Packard; James Shepherd; Allan Gaw
BackgroundWe examined the development of new diabetes mellitus in men aged 45 to 64 years during the West of Scotland Coronary Prevention Study. Methods and ResultsOur definition of diabetes mellitus was based on the American Diabetic Association threshold of a blood glucose level of ≥7.0 mmol/L. Subjects who self-reported diabetes at baseline or had a baseline glucose level of ≥7.0 mmol/L were excluded from the analyses. A total of 5974 of the 6595 randomized subjects were included in the analysis, and 139 subjects became diabetic during the study. The baseline predictors of the transition from normal glucose control to diabetes were studied. In the univariate model, body mass index, log triglyceride, log white blood cell count, systolic blood pressure, total and HDL cholesterol, glucose, and randomized treatment assignment to pravastatin were significant predictors. In a multivariate model, body mass index, log triglyceride, glucose, and pravastatin therapy were retained as predictors of diabetes in this cohort. ConclusionsWe concluded that the assignment to pravastatin therapy resulted in a 30% reduction (P =0.042) in the hazard of becoming diabetic. By lowering plasma triglyceride levels, pravastatin therapy may favorably influence the development of diabetes, but other explanations, such as the anti-inflammatory properties of this drug in combination with its endothelial effects, cannot be excluded with these analyses.
Journal of Human Hypertension | 2003
Cath Stirling; J. Houston; Stuart Robertson; James Boyle; A. Allan; John Norrie; C Isles
The occurrence of severe acute renal failure in 3 patients who developed diarrhoea while taking angiotensin converting enzyme (ACE) inhibitors led us to undertake a retrospective cohort survey to determine the frequency with which diarrhoea and vomiting are associated with acute renal failure in patients taking this class of drug. Serum creatinine was measured as part of the diagnostic workup of 2398 consecutive admissions to an acute medical receiving unit in a district general hospital. Outcome measures were the presence of diarrhoea and/or vomiting, and whether taking an ACE inhibitor, NSAID or diuretic at the time of admission, also previous, initial and follow up serum creatinine concentrations. Peak serum creatinine in the 3 cases was 1159, 989 and 765 μmol/l. None of the 3 required dialysis and all recovered renal function completely after receiving large volumes of intravenous fluid. In the cohort study, 89 of 2398(3.7%) admissions had serum creatinine ⩾200 μmol/l. Nine were regular dialysis patients. Of the remaining patients, 30 (37.5%) were taking an ACE inhibitor. Six of 30 (20%) gave a history of diarrhoea and/or vomiting. Median creatinine concentration in this group was 135 (range 111–209) μmol/l before admission, 292 (216–724) μmol/l when first seen in hospital, and 134 (94–219) μmol/l following the withdrawal of drug therapy and fluid replacement. In conclusion, volume depletion causing acute renal failure in patients taking ACE inhibitors is not uncommon. Such patients and their general practitioners should be aware that reversible renal impairment may occur during intercurrent illnesses, particularly if characterised by diarrhoea and/or vomiting.
Circulation | 1998
Christopher J. Packard; James Shepherd; Stuart M. Cobbe; Jane B. Ford; C Isles; J. H. McKillop; Peter W. Macfarlane; Ar Lorimer; John Norrie; W Scotland Coronary Prevention Study Grp
Atherosclerosis Supplements | 2004
James Shepherd; Stuart M. Cobbe; Ian Ford; C Isles; A.Ross Lorimer; Peter W. Macfarlane; J. H. McKillop; Christopher J. Packard
The Lancet | 1996
James Shepherd; Stuart M. Cobbe; Ar Lorimer; J. H. McKillop; Jane B. Ford; Christopher J. Packard; Peter W. Macfarlane; C Isles; Mf Oliver; Af Lever; Bw Brown; Jgg Ledingham; Sj Pocock; Basil M. Rifkind; Bd Vallance; D Ballantyne; L Anderson; D Duncan; Sharon Kean; A Lawrence; J McGrath; K Montgomery; John Norrie; M Percy; E Pomphrey; A Whitehouse; P Cameron; P Parker; F Porteous; L Fletcher
European Heart Journal | 1997
James Shepherd; Stuart M. Cobbe; Ar Lorimer; J. H. McKillop; Jane B. Ford; Christopher J. Packard; Peter W. Macfarlane; C Isles; Mf Oliver; Af Lever; Bw Brown; Jgg Ledingham; Sj Pocock; Basil M. Rifkind; Bd Vallance; D Ballantyne; L Anderson; D Duncan; Sharon Kean; A Lawrence; J McGrath; K Montgomery; John Norrie; M Percy; E Pomphrey; A Whitehouse; P Cameron; P Parker; F Porteous; L Fletcher
American Journal of Cardiology | 1995
Sm Cobbe; Ar Lorimer; J. H. McKillop; Christopher J. Packard; Peter W. Macfarlane; C Isles; Mf Oliver; Af Lever; Bw Brown; Jgg Ledingham; Sj Pocock; Basil M. Rifkind; Bd Vallance; D Ballantyne; John Norrie
Archive | 1995
James Shepherd; Stuart M. Cobbe; Ian Ford; C Isles; A.Ross Lorimer; Peter W. Macfarlane; J. H. McKillop; Chris J. Packard
Health bulletin | 2001
A. Brammah; G. Young; A. Allan; Stuart Robertson; John Norrie; C Isles
The Lancet | 1997
T. A. Barringer; C Isles; Stuart M. Cobbe; Ian Ford